Evidence map›Paper›PMID 32677983›Full record

ArticleJournal of orthopaedic surgery and research2020

Outcome of osteofibrous dysplasia-like versus classic adamantinoma of long bones: a single-institution experience.

Zhiping Deng, Lihua Gong, Qing Zhang, Lin Hao, Yi Ding, Xiaohui Niu

Open access · goldAbstract read
In one paragraph

Article in Journal of orthopaedic surgery and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Osteofibrous dysplasia: a narrative review.Journal of orthopaedic surgery and research · 2024
    Review
  4. Tibial Adamantinoma: A Case Report from a Resource-Limited-Setting.International medical case reports journal · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Recurrent Adamantinoma With Fibrous Dysplasia-like Feature.Clinical pathology (Thousand Oaks, Ventura County, Calif.)
    Article
  9. Adamantinoma: An Updated Review.In vivo (Athens, Greece)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zhiping DengDepartment of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Number 31, Xinjiekoudongjie Street, Xicheng District, Beijing, 100035, China.
Lihua GongDepartment of Pathology, Beijing Jishuitan Hospital, Peking University, Beijing, China.
Qing ZhangDepartment of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Number 31, Xinjiekoudongjie Street, Xicheng District, Beijing, 100035, China.
Lin HaoDepartment of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Number 31, Xinjiekoudongjie Street, Xicheng District, Beijing, 100035, China.
Yi DingDepartment of Pathology, Beijing Jishuitan Hospital, Peking University, Beijing, China.
Xiaohui NiuDepartment of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Number 31, Xinjiekoudongjie Street, Xicheng District, Beijing, 100035, China. niuxiaohui@263.net.
Peking University · CNBeijing Jishuitan Hospital · CN

Funding

Academic New Star Program of Beijing Jishuitan Hospital No XKXX201610Beijing Talents Fund 2017000021469G239
6 · The paper itself

Abstract

backgroundThe clinical and molecular characteristics of osteofibrous dysplasia (OFD)-like adamantinoma (AD) differ from those of classic AD. Most reports about OFD-like AD are case reports or small case series. More cases from different centers are still warranted.

methodsThe orthopedic oncology database of our institution was searched to identify patients with AD. The cases of OFD-like and classic AD of the long bones were retrospectively analyzed. Between December 1999 and August 2016, 23 patients were treated for AD, comprising seven with OFD-like AD and 16 with classic AD. The outcomes were compared between AD subtypes.

resultsIn the OFD-like AD group, four lesions were treated with extensive curettage, while three were treated with wide resection. The median follow-up duration in the OFD-like AD group was 66 months (range 43-131 months). At the end of follow-up, there was only one case of local recurrence (LR) in the OFD-like AD group, giving a LR rate of 14.3% (1/7). No distant metastasis or progression to classic AD was detected in the OFD-like AD group. In the classic AD group, the treatments were below-the-knee amputation in one patient with extensive tibial and fibular lesions, curettage with a bone graft in one patient who was diagnosed with OFD based on a core needle biopsy, hemi-cortical excision and reconstruction in two patients, and segmental resection and reconstruction in 12 patients. At the end of follow-up, there were three cases of LR in the classic AD group, giving a LR rate of 18.8% (3/16); two patients developed lung metastasis after LR and died of the disease at 88 and 126 months after the first surgery in our hospital, respectively. The classic AD group had a metastatic rate of 12.5% (2/16), a final limb salvage rate of 75%, and estimated 5- and 10-year survival rates of 88.9% and 77.1%, respectively.

conclusionsOFD-like AD has a better outcome than classic AD. For OFD-like AD, extensive curettage is suggested if the tumor extent allows. For classic AD, aggressive resection with wide margins is essential to achieve local control. A long-term follow-up is necessary due to the possibility of late complications.

Indexed as

AdamantinomaBone Diseases, DevelopmentalAdolescentAdultFemaleFollow-Up StudiesHumansMaleMargins of ExcisionOrthopedic ProceduresPlastic Surgery ProceduresRetrospective StudiesSurvival RateTime FactorsTreatment OutcomeYoung AdultAdamantinomaBone sarcomaNeoplasmOncologyOsteofibrous dysplasia-like adamantinoma

Identifiers

PMID32677983
PMCPMC7367244
OpenAlexW3042786671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.